ASCO® 2026 Highlights: Presenter Vignette – Andrew Armstrong
Andrew Armstrong
MD, MS
Duke University Medical Center
5016
Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).